Jochen Zwerina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jochen Zwerina has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Georg Schett
Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Department of Nephrology, Medical University Hannover, Hannover, Germany, Department of Internal Medicine 3, University Hospital, Jena, Germany, Institute of Psychosocial Medicine and Psychotherapy, University Hospital, Jena, Germany and Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Center Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria
9 shared publicationsBernhard Manger
4 shared publications- Georg Schett
Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
4 shared publications Gisela Ruiz Heiland
Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nurnberg, Germany
3 shared publicationsKarin Polzer
University of Erlangen-Nuremberg, Erlangen, Germany
3 shared publications- Alexander Rupert Moschen
Department of Internal Medicine 2 (Gastroenterology and Hepatology, Endocrinology and Metabolism, Nephrology, Rheumatology), Faculty of Medicine, Johannes Kepler University Linz, 4020 Linz, Austria
2 shared publications
Latest Publications
- 17 October 2013
- Vol. 31 (6) , 989-90
Can ANCA differentiate eosinophilic granulomatosis with polyangiitis (Churg-Strauss) from idiopathic hypereosinophilic syndrome?
- 17 October 2013
- Vol. 31 (6) , 989-90
Can ANCA differentiate eosinophilic granulomatosis with polyangiitis (Churg-Strauss) from idiopathic hypereosinophilic syndrome?
- Open Access
- 10 July 2013
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 52 (10) , 1856-1864
Coping strategies and depressiveness in primary systemic vasculitis—what is their impact on health-related quality of life?
Objective. To investigate the influence of disease-related coping strategies and depressiveness on health-related quality of life (HRQOL) in primary systemic vasculitis (PSV) patients. Methods. One hundred and twenty-two patients with definite diagnosis of PSV were examined in a cross-sectional study. HRQOL (SF-36), depressiveness (BDI), illness perception (B-IPQ) and coping strategies (FKV-LIS) were measured using validated instruments. Additional disease-related and demographic data were retrieved from the patients’ records. Results. HRQOL in PSV patients was reduced compared with the SF-36 norm sample. Specific organ manifestation, size of vessel involvement and disease activity were not related to HRQOL. Linear regression modelling revealed a questionable relationship of emotional to physical HRQOL (P = 0.003, potential suppression effect of BDI), whereas both domains were influenced by depressiveness (P ≤ 0.001). Physical HRQOL was additionally related to fatigue and widowed marital status, while emotional HRQOL was associated with a depressive coping style. Conclusion. HRQOL is impaired in PSV as compared with the general population. Current depressiveness strongly affects physical as well as mental HRQOL. Cognitive intervention strategies should be established in order to improve quality of life in PSV patients.
- 10 July 2013
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 52 (10) , 1856-1864
Open AccessCoping strategies and depressiveness in primary systemic vasculitis—what is their impact on health-related quality of life?
Objective. To investigate the influence of disease-related coping strategies and depressiveness on health-related quality of life (HRQOL) in primary systemic vasculitis (PSV) patients. Methods. One hundred and twenty-two patients with definite diagnosis of PSV were examined in a cross-sectional study. HRQOL (SF-36), depressiveness (BDI), illness perception (B-IPQ) and coping strategies (FKV-LIS) were measured using validated instruments. Additional disease-related and demographic data were retrieved from the patients’ records. Results. HRQOL in PSV patients was reduced compared with the SF-36 norm sample. Specific organ manifestation, size of vessel involvement and disease activity were not related to HRQOL. Linear regression modelling revealed a questionable relationship of emotional to physical HRQOL (P = 0.003, potential suppression effect of BDI), whereas both domains were influenced by depressiveness (P ≤ 0.001). Physical HRQOL was additionally related to fatigue and widowed marital status, while emotional HRQOL was associated with a depressive coping style. Conclusion. HRQOL is impaired in PSV as compared with the general population. Current depressiveness strongly affects physical as well as mental HRQOL. Cognitive intervention strategies should be established in order to improve quality of life in PSV patients.
- Open Access
- 18 February 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e56316
The Mitogen-Activated Protein Kinase p38α Regulates Tubular Damage in Murine Anti-Glomerular Basement Membrane Nephritis
P38 mitogen-activated protein kinase (MAPK) is thought to play a central role in acute and chronic inflammatory responses. Whether p38MAPK plays a pathogenic role in crescentic GN (GN) and which of its four isoforms is preferentially involved in kidney inflammation is not definitely known. We thus examined expression and activation of p38MAPK isoforms during anti-glomerular basement membrane (GBM) nephritis. Therefore, p38α conditional knockout mice (MxCre-p38αΔ/Δ) were used to examine the role of p38α in anti-GBM induced nephritis. Both wild type and MxCre-p38αΔ/Δ mice developed acute renal failure over time. Histological examinations revealed a reduced monocyte influx and less tubular damage in MxCre-p38αΔ/Δ mice, whereas glomerular crescent formation and renal fibrosis was similar. Likewise, the levels of pro- and anti-inflammatory cytokines such as TNF, IL-1 and IL-10 were similar, but IL-8 was even up-regulated in MxCre-p38αΔ/Δ mice. In contrast, we could detect strong down-regulation of chemotactic cytokines such as CCL-2, -5 and -7, in the kidneys of MxCre-p38αΔ/Δ mice. In conclusion, p38α is the primary p38MAPK isoform expressed in anti-GBM nephritis and selectively affects inflammatory cell influx and tubular damage. Full protection from nephritis is however not achieved as renal failure and structural damage still occurs.
- 18 February 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e56316
Open AccessThe Mitogen-Activated Protein Kinase p38α Regulates Tubular Damage in Murine Anti-Glomerular Basement Membrane Nephritis
P38 mitogen-activated protein kinase (MAPK) is thought to play a central role in acute and chronic inflammatory responses. Whether p38MAPK plays a pathogenic role in crescentic GN (GN) and which of its four isoforms is preferentially involved in kidney inflammation is not definitely known. We thus examined expression and activation of p38MAPK isoforms during anti-glomerular basement membrane (GBM) nephritis. Therefore, p38α conditional knockout mice (MxCre-p38αΔ/Δ) were used to examine the role of p38α in anti-GBM induced nephritis. Both wild type and MxCre-p38αΔ/Δ mice developed acute renal failure over time. Histological examinations revealed a reduced monocyte influx and less tubular damage in MxCre-p38αΔ/Δ mice, whereas glomerular crescent formation and renal fibrosis was similar. Likewise, the levels of pro- and anti-inflammatory cytokines such as TNF, IL-1 and IL-10 were similar, but IL-8 was even up-regulated in MxCre-p38αΔ/Δ mice. In contrast, we could detect strong down-regulation of chemotactic cytokines such as CCL-2, -5 and -7, in the kidneys of MxCre-p38αΔ/Δ mice. In conclusion, p38α is the primary p38MAPK isoform expressed in anti-GBM nephritis and selectively affects inflammatory cell influx and tubular damage. Full protection from nephritis is however not achieved as renal failure and structural damage still occurs.
- Open Access
- 20 November 2012
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 28 (4) , 936-947
Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover
The objective of this study was to investigate the role of the serine‐threonine kinase mitogen‐activated protein kinase 2 (MK2) in bone homeostasis. Primary bone cell cultures from MK2+/+ and MK2–/– mice were assessed for osteoclast and osteoblast differentiation, bone resorption, and gene expression. Bone architecture of MK2+/+ and MK2–/– mice was investigated by micro–computed tomography and histomorphometry. Ovariectomy was performed in MK2+/+ and MK2–/– mice to assess the role of MK2 in postmenopausal bone loss. Osteoclastogenesis, bone resorption, and osteoclast gene expression were significantly impaired in monocytes from MK2–/– compared to MK2+/+ mice. Mechanistically, loss of MK2 causes impaired DNA binding of c‐fos and nuclear factor of activated T cells cytoplasmic 1 (NFATc1) to tartrate‐resistant acid phosphatase (TRAP) and the calcitonin receptor gene promoter. In addition, MK2–/– mice showed an age‐dependent increase in trabecular bone mass and cortical thickness, fewer osteoclasts, and lower markers of bone resorption than MK2+/+ mice. Furthermore, MK2–/– mice were protected from ovariectomy‐induced bone loss. Osteoblastogenesis and bone formation were unchanged in MK2–/– mice, whereas osteoblast expression of osteoprotegerin (OPG) and serum levels of OPG were higher in MK2–/– than in MK2+/+ mice. Loss of MK2 effectively blocks bone resorption and prevents the development of postmenopausal bone loss. Small‐molecule inhibitors of MK2 could thus emerge as highly effective tools to block bone resorption and to treat postmenopausal bone loss. © 2013 American Society for Bone and Mineral Research.
- 20 November 2012
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 28 (4) , 936-947
Open AccessMitogen-activated protein kinase 2 regulates physiological and pathological bone turnover
The objective of this study was to investigate the role of the serine‐threonine kinase mitogen‐activated protein kinase 2 (MK2) in bone homeostasis. Primary bone cell cultures from MK2+/+ and MK2–/– mice were assessed for osteoclast and osteoblast differentiation, bone resorption, and gene expression. Bone architecture of MK2+/+ and MK2–/– mice was investigated by micro–computed tomography and histomorphometry. Ovariectomy was performed in MK2+/+ and MK2–/– mice to assess the role of MK2 in postmenopausal bone loss. Osteoclastogenesis, bone resorption, and osteoclast gene expression were significantly impaired in monocytes from MK2–/– compared to MK2+/+ mice. Mechanistically, loss of MK2 causes impaired DNA binding of c‐fos and nuclear factor of activated T cells cytoplasmic 1 (NFATc1) to tartrate‐resistant acid phosphatase (TRAP) and the calcitonin receptor gene promoter. In addition, MK2–/– mice showed an age‐dependent increase in trabecular bone mass and cortical thickness, fewer osteoclasts, and lower markers of bone resorption than MK2+/+ mice. Furthermore, MK2–/– mice were protected from ovariectomy‐induced bone loss. Osteoblastogenesis and bone formation were unchanged in MK2–/– mice, whereas osteoblast expression of osteoprotegerin (OPG) and serum levels of OPG were higher in MK2–/– than in MK2+/+ mice. Loss of MK2 effectively blocks bone resorption and prevents the development of postmenopausal bone loss. Small‐molecule inhibitors of MK2 could thus emerge as highly effective tools to block bone resorption and to treat postmenopausal bone loss. © 2013 American Society for Bone and Mineral Research.
- Open Access
- 21 November 2011
- Published by Wiley in European Journal of Immunology
- Vol. 42 (2) , 413-423
Anti IL‐17A therapy inhibits bone loss in TNF‐α‐mediated murine arthritis by modulation of the T‐cell balance
Tumour necrosis factor alpha (TNF‐α) is a major inducer for inflammation and bone loss. Here, we investigated whether interleukin (IL)‐17 plays a role in TNF‐α‐mediated inflammation and bone resorption. Human TNF‐α transgenic (hTNFtg) mice were treated with a neutralizing anti‐IL‐17A antibody and assessed for inflammation, cartilage and bone damage. T‐cell transcription factors and lymphokine patterns were measured in the LNs. IL‐17A inhibition in the absence of IL‐1 was also evaluated by treating hTNFtg/IL‐1−/− mice with an IL‐17A neutralizing antibody. IL‐17A neutralization had only minor effects on TNF‐α‐induced inflammation but effectively reduced local and systemic bone loss by blocking osteoclast differentiation in vivo. Effects were based on a shift to bone‐protective T‐cell responses such as enhanced Th2 differentiation, IL‐4 and IL‐12 expression and Treg cell numbers. Whereas inflammation in hTNFtg/IL‐1−/− mice was highly sensitive to IL‐17A blockade, no shift in the T‐cell lineages and no additional benefit on bone mass were observed in response to IL‐17A neutralization. We thus conclude that IL‐17A is a key mediator of TNF‐α‐induced bone loss by closely interacting with IL‐1 in blocking bone protective T‐cell responses.
- 21 November 2011
- Published by Wiley in European Journal of Immunology
- Vol. 42 (2) , 413-423
Open AccessAnti IL‐17A therapy inhibits bone loss in TNF‐α‐mediated murine arthritis by modulation of the T‐cell balance
Tumour necrosis factor alpha (TNF‐α) is a major inducer for inflammation and bone loss. Here, we investigated whether interleukin (IL)‐17 plays a role in TNF‐α‐mediated inflammation and bone resorption. Human TNF‐α transgenic (hTNFtg) mice were treated with a neutralizing anti‐IL‐17A antibody and assessed for inflammation, cartilage and bone damage. T‐cell transcription factors and lymphokine patterns were measured in the LNs. IL‐17A inhibition in the absence of IL‐1 was also evaluated by treating hTNFtg/IL‐1−/− mice with an IL‐17A neutralizing antibody. IL‐17A neutralization had only minor effects on TNF‐α‐induced inflammation but effectively reduced local and systemic bone loss by blocking osteoclast differentiation in vivo. Effects were based on a shift to bone‐protective T‐cell responses such as enhanced Th2 differentiation, IL‐4 and IL‐12 expression and Treg cell numbers. Whereas inflammation in hTNFtg/IL‐1−/− mice was highly sensitive to IL‐17A blockade, no shift in the T‐cell lineages and no additional benefit on bone mass were observed in response to IL‐17A neutralization. We thus conclude that IL‐17A is a key mediator of TNF‐α‐induced bone loss by closely interacting with IL‐1 in blocking bone protective T‐cell responses.
- Open Access
- 28 July 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (4) , 235-11
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis
Bone destruction is a frequent and clinically serious event in patients with rheumatoid arthritis (RA). Local joint destruction can cause joint instability and often necessitates reconstructive or replacement surgery. Moreover, inflammation-induced systemic bone loss is associated with an increased fracture risk. Bone resorption is a well-controlled process that is dependent on the differentiation of monocytes to bone-resorbing osteoclasts. Infiltrating as well as resident synovial cells, such as T cells, monocytes and synovial fibroblasts, have been identified as sources of osteoclast differentiation signals in RA patients. Pro-inflammatory cytokines are amongst the most important mechanisms driving this process. In particular, macrophage colony-stimulating factor, RANKL, TNF, IL-1 and IL-17 may play dominant roles in the pathogenesis of arthritis-associated bone loss. These cytokines activate different intracellular pathways to initiate osteoclast differentiation. Thus, over the past years several promising targets for the treatment of arthritic bone destruction have been defined.
- 28 July 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (4) , 235-11
Open AccessPositive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis
Bone destruction is a frequent and clinically serious event in patients with rheumatoid arthritis (RA). Local joint destruction can cause joint instability and often necessitates reconstructive or replacement surgery. Moreover, inflammation-induced systemic bone loss is associated with an increased fracture risk. Bone resorption is a well-controlled process that is dependent on the differentiation of monocytes to bone-resorbing osteoclasts. Infiltrating as well as resident synovial cells, such as T cells, monocytes and synovial fibroblasts, have been identified as sources of osteoclast differentiation signals in RA patients. Pro-inflammatory cytokines are amongst the most important mechanisms driving this process. In particular, macrophage colony-stimulating factor, RANKL, TNF, IL-1 and IL-17 may play dominant roles in the pathogenesis of arthritis-associated bone loss. These cytokines activate different intracellular pathways to initiate osteoclast differentiation. Thus, over the past years several promising targets for the treatment of arthritic bone destruction have been defined.
- 25 January 2011
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (10) , 1823-1827
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study
To determine the potential of eotaxin-3 as a diagnostic marker for active disease and genetic susceptibility factor for Churg-Strauss syndrome (CSS). A total of 37 patients with active, relapsed or inactive CSS, 123 healthy controls and 138 disease controls were studied. Clinical data were collected and serum levels of eotaxin-3 were determined. Ex vivo stability of eotaxin-3 in serum samples was tested. Furthermore, the association of single nucleotide polymorphisms (SNPs) in the eotaxin-3 gene with CSS was determined in 161 CSS patients and 124 healthy controls. Serum eotaxin-3 was highly elevated in active CSS patients. Neither eosinophilic diseases nor other small-vessel vasculitides were associated with high serum eotaxin-3 levels. Receiver operating characteristic curve analysis determined a sensitivity and specificity of 87.5 and 98.6% at a cut-off level of 80 pg/ml. None of the tested SNPs within the eotaxin-3 gene influenced the susceptibility to develop CSS. Serum eotaxin-3 is a sensitive and specific marker for the diagnosis of active CSS suitable for routine clinical practice. Previously described SNPs in the eotaxin-3 gene do not predict the risk of developing CSS.
- 25 January 2011
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (10) , 1823-1827
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study
To determine the potential of eotaxin-3 as a diagnostic marker for active disease and genetic susceptibility factor for Churg-Strauss syndrome (CSS). A total of 37 patients with active, relapsed or inactive CSS, 123 healthy controls and 138 disease controls were studied. Clinical data were collected and serum levels of eotaxin-3 were determined. Ex vivo stability of eotaxin-3 in serum samples was tested. Furthermore, the association of single nucleotide polymorphisms (SNPs) in the eotaxin-3 gene with CSS was determined in 161 CSS patients and 124 healthy controls. Serum eotaxin-3 was highly elevated in active CSS patients. Neither eosinophilic diseases nor other small-vessel vasculitides were associated with high serum eotaxin-3 levels. Receiver operating characteristic curve analysis determined a sensitivity and specificity of 87.5 and 98.6% at a cut-off level of 80 pg/ml. None of the tested SNPs within the eotaxin-3 gene influenced the susceptibility to develop CSS. Serum eotaxin-3 is a sensitive and specific marker for the diagnosis of active CSS suitable for routine clinical practice. Previously described SNPs in the eotaxin-3 gene do not predict the risk of developing CSS.
- Open Access
- 10 January 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (4) , 1287-1297
Transcription factor Fra-1 induces cholangitis and liver fibrosis
Chronic diseases of the biliary system are common and may cause fibrosis and eventually progression to liver cirrhosis. The aim was to define a new mouse model of a cholangiopathy leading to liver fibrosis in fra-1tg mice. Liver pathology of fra-1tg mice was analyzed in detail by histology and flow cytometry. Transcript levels of fibrosis-related genes and matrix metalloproteinase (MMP) activities were quantified and immunohistochemical analysis additionally applied. The role of the immune system in this model was analyzed by crossing fra-1tg mice with rag2 -/- mice. Furthermore, expression of Fra-1 in corresponding human liver diseases was investigated on transcription level and histologically. Fra-1tg mice spontaneously develop biliary fibrosis preceded by ductular proliferation and infiltration of inflammatory cells. Fra-1 protein is present in cholangiocytes and inflammatory cells within the liver. These findings were replicated in human biopsies of patients with advanced liver fibrosis. The inflammatory infiltrate showed a strong increase in activated T cells and decreased natural killer (NK), natural killer T cells (NKT), and B cells in fra-1tg mice as compared to wildtype mice. Moreover, fra-1tg mice develop biliary fibrosis with a time-dependent increase in hepatic collagen content and increase in relative messenger RNA (mRNA) expression of profibrotic genes. Attenuation but not complete prevention of collagen accumulation in liver was observed in the fra-1tg × rag2-/- mice. However, transplantation of fra-1tg bone marrow cells into wildtype mice could not induce disease. Conclusion: Fra-1tg mice spontaneously develop a progressive biliary disease. These mice are an attractive model for the investigation of cholangiopathies and their interaction with the immune system. (HEPATOLOGY 2011;)
- 10 January 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (4) , 1287-1297
Open AccessTranscription factor Fra-1 induces cholangitis and liver fibrosis
Chronic diseases of the biliary system are common and may cause fibrosis and eventually progression to liver cirrhosis. The aim was to define a new mouse model of a cholangiopathy leading to liver fibrosis in fra-1tg mice. Liver pathology of fra-1tg mice was analyzed in detail by histology and flow cytometry. Transcript levels of fibrosis-related genes and matrix metalloproteinase (MMP) activities were quantified and immunohistochemical analysis additionally applied. The role of the immune system in this model was analyzed by crossing fra-1tg mice with rag2 -/- mice. Furthermore, expression of Fra-1 in corresponding human liver diseases was investigated on transcription level and histologically. Fra-1tg mice spontaneously develop biliary fibrosis preceded by ductular proliferation and infiltration of inflammatory cells. Fra-1 protein is present in cholangiocytes and inflammatory cells within the liver. These findings were replicated in human biopsies of patients with advanced liver fibrosis. The inflammatory infiltrate showed a strong increase in activated T cells and decreased natural killer (NK), natural killer T cells (NKT), and B cells in fra-1tg mice as compared to wildtype mice. Moreover, fra-1tg mice develop biliary fibrosis with a time-dependent increase in hepatic collagen content and increase in relative messenger RNA (mRNA) expression of profibrotic genes. Attenuation but not complete prevention of collagen accumulation in liver was observed in the fra-1tg × rag2-/- mice. However, transplantation of fra-1tg bone marrow cells into wildtype mice could not induce disease. Conclusion: Fra-1tg mice spontaneously develop a progressive biliary disease. These mice are an attractive model for the investigation of cholangiopathies and their interaction with the immune system. (HEPATOLOGY 2011;)
- Open Access
- 6 December 2010
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (3) , 670-680
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis
Objective The proteasome inhibitor bortezomib has potent anti-myeloma and bone-protective activity. Recently, bortezomib was shown to directly inhibit osteoclastogenesis. The aim of this study was to analyze the influence and therapeutic effect of bortezomib in a mouse model of inflammatory arthritis. Methods Heterozygous human tumor necrosis factor α (hTNFα)–transgenic mice and their wild-type (WT) littermates were intravenously injected with 0.75 mg/kg of bortezomib or phosphate buffered saline twice weekly. The mice were assessed for clinical signs of arthritis. After 6 weeks of treatment, mice were analyzed for synovial inflammation, cartilage damage, bone erosions, and systemic bone changes. Osteoclast precursors from WT and hTNF-transgenic mice were isolated from bone marrow, treated with bortezomib, and analyzed for osteoclast differentiation, bone resorption, and expression of osteoclast-specific genes as well as apoptosis and ubiquitination. Results Bortezomib-treated hTNF-transgenic mice showed moderately increased inflammatory activity and dramatically enhanced bone erosions associated with a significant increase in the number of synovial osteoclasts. Interestingly, bortezomib did not alter systemic bone turnover in either hTNF-transgenic mice or WT mice. In vitro, treatment with therapeutically relevant concentrations of bortezomib resulted in increased differentiation of monocytes into osteoclasts and more resorption pits. Molecularly, bortezomib increased the expression of TNF receptor−associated factor 6, c-Fos, and nuclear factor of activated T cells c1 in osteoclast precursors. Conclusion In TNF-mediated bone destruction, bortezomib treatment increased synovial osteoclastogenesis and bone destruction. Hence, proteasome inhibition may have a direct bone-resorptive effect via stimulation of osteoclastogenesis during chronic arthritis.
- 6 December 2010
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (3) , 670-680
Open AccessProteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis
Objective The proteasome inhibitor bortezomib has potent anti-myeloma and bone-protective activity. Recently, bortezomib was shown to directly inhibit osteoclastogenesis. The aim of this study was to analyze the influence and therapeutic effect of bortezomib in a mouse model of inflammatory arthritis. Methods Heterozygous human tumor necrosis factor α (hTNFα)–transgenic mice and their wild-type (WT) littermates were intravenously injected with 0.75 mg/kg of bortezomib or phosphate buffered saline twice weekly. The mice were assessed for clinical signs of arthritis. After 6 weeks of treatment, mice were analyzed for synovial inflammation, cartilage damage, bone erosions, and systemic bone changes. Osteoclast precursors from WT and hTNF-transgenic mice were isolated from bone marrow, treated with bortezomib, and analyzed for osteoclast differentiation, bone resorption, and expression of osteoclast-specific genes as well as apoptosis and ubiquitination. Results Bortezomib-treated hTNF-transgenic mice showed moderately increased inflammatory activity and dramatically enhanced bone erosions associated with a significant increase in the number of synovial osteoclasts. Interestingly, bortezomib did not alter systemic bone turnover in either hTNF-transgenic mice or WT mice. In vitro, treatment with therapeutically relevant concentrations of bortezomib resulted in increased differentiation of monocytes into osteoclasts and more resorption pits. Molecularly, bortezomib increased the expression of TNF receptor−associated factor 6, c-Fos, and nuclear factor of activated T cells c1 in osteoclast precursors. Conclusion In TNF-mediated bone destruction, bortezomib treatment increased synovial osteoclastogenesis and bone destruction. Hence, proteasome inhibition may have a direct bone-resorptive effect via stimulation of osteoclastogenesis during chronic arthritis.